This is an HTML version of an attachment to the Official Information request 'Public information regarding puberty blockers'.


133 Molesworth Street 
PO Box 5013 
Wellington 6140 
19 October 2020
New Zealand 
T+64 4 496 2000 
K Issac 
By email: 
[FYI request #13869 email] 
Ref:  
H202007421 
Dear K Issac 
Response to your request for official information 
Thank you for your request under the Official Information Act 1982 (the Act) to the Ministry of 
Health (the Ministry) on 26 September 2020 for: 
“On what clinical and evidential basis do you state (in reference to puberty blockers) that 
they are a "safe and fully reversible medicine" when the NHS guidance in the UK states 
that "Little is known about the long-term side effects of hormone or puberty blockers in 
children with gender dysphoria" 

The Ministry refers to the Guidelines for Gender Affirming Healthcare for Gender Diverse and 
Transgender Children, Young People and Adults in Aotearoa New Zealand
 available on the 
University of Waikato’s Research Commons’ website: 
https://researchcommons.waikato.ac.nz/handle/10289/12160. This guide for gender-affirming 
health care was developed by an independent group of health professionals and community 
stakeholders and states on page 29 that ‘puberty blockers are considered to be fully reversible’. 
The Ministry also notes that Standards of Care developed by the World Professional 
Association for Transgender Health (WPATH) lists the use of GnRH analogues to suppress 
estrogen or testosterone production and consequently delay the physical changes of puberty as 
‘fully reversible intervention’. Please refer to page 18 at the following link: 
https://www.wpath.org/publications/soc. 
It is important to note that the Ministry’s website is intended to provide general health advice. 
For the treatment of young transgender New Zealanders, it is the responsibility of the treating 
clinician to consider the appropriateness of a particular treatment for a particular patient, and to 
ensure that the patient is informed of the risks and benefits associated with that treatment. 
Informed consent should be obtained by the clinician from the patient before the choice is made 
to prescribe the medicine.  
I trust this information fulfils your request. Under section 28(3) of the Act you have the right to 
ask the Ombudsman to review any decisions made under this request. 
Please note that this response, with your personal details removed, may be published on the 
Ministry website. 
Yours sincerely 
Dr Andrew Simpson 
Chief Medical Officer